Purdue and Sackler family agree to $7.4bn national opioid settlement
The settlement ends the Sackler family’s ownership of the Oxycontin developer Purdue Pharma.
Drug Manufacturers
FDA review designations: tracking 40 years of innovation
JPM 2025: Lonza shares outlook on CHI exit and acquisition strategy
“Nothing to do with geopolitics”: WuXi Biologics CEO bullish in face of Biosecure
JPM 2025: WuXi AppTec rebuffs concern about lower GLP-1 demand after Lilly’s low revenue forecast
Charles River CEO reveals drop in 2025 revenue outlook at JP Morgan
Petrovax announces positive results from long-CoV-III-21 trial of Longidaza for long-term pulmonary sequelae of COVID-19
ADCs breach barriers to become mainstream cancer treatment
